Dr. Beher, CEO will lecture on the potential of O-GlcNAcase Inhibitors for Tauopathies on November 4, 2016 in Cambridge, United Kingdom.c
Posted :
Dr. Beher, CEO will lecture on O-GlcNAcase Inhibitors for Tauopathies.
The International Conference on Alzheimer’s Drug Discovery brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer’s disease and related dementias. The ADDF’s funded investigators and top-level scientists in the field will present on their current research progress and stimulate discussion.
Posted :
Dr. Christoph Wiessner, COO will participate in a panel discussion on the update and future directions on clinical trials in Frontotemporal Dementia and associated disorders.
Posted :
Dr. Dirk Beher, CEO will present on Founding and Funding of a Biotechnology Company. The Alzheimer’s Drug Discovery Foundation is hosting its first European conference on Drug Discovery for Neurodegeneration: An Educational Course on Translating Research into Drugs which is based on the ADDF’s annual US-based Drug Discovery for Neurodegeneration conference.
Posted :
Asceneuron presents the novel M1-targeting compound ASN-51 at the 11th International Conference on Alzheimer’s and Parkinson’s disease held 6-10 March 2013 in Florence, Italy.
Read the comments in the Alzheimer Reseach Forum News of March 26th, 2013: click here
Posted :